Abstract Submission
- The organizing committee of the 57th Annual Scientific Meeting of the Japan Atherosclerosis Society encourages the submission of abstracts widely from abroad.
- All abstracts submitted are peer-reviewed and selected for presentation by the organizing committee.
Abstract Submission Period
- Wednesday, December 25, 2024, 10:00 a.m. ー Wednesday, January 29, 2025, noon
- Submissions, modifications, or deletions of abstracts will not be accepted after the deadline.
Traffic to the submission system is expected to be heavy close to the deadline, which may cause a delay in processing the submission of your abstract. We recommend submitting your abstracts as early as possible. - You are able to modify your abstract contents submitted online until the deadline. Please note that you may not be able to make modifications just before the deadline due to heavy traffic.
- Changes, such as to the names of co-authors, after the deadline will not be accepted.
Please complete those corrections during the abstract submission period.
Grant for Participants from Overseas
- The grant applicants must be those who belong to overseas institutions and are under the age of 40 (Age 40 not included) at the time of presentation (July 5-6, 2025).
- The applicants from overseas affiliations will be evaluated from the abstract and up to ten (10) most outstanding researchers on atherosclerosis will receive a grant of JPY 100,000.
- Please note that if the conference is webcast and you do not present at the venue, you will not receive a Travel Grant.
- To apply for a grant, you will need to provide your abstract registration number and proof of age (e.g. passport, driver’s license, ID card).
- Please send your abstract registration number and proof of age (copy of passport, driver’s license, ID card, etc.) to the email address below.
- The 57th Annual Scientific Meeting of the Japan Atherosclerosis Society
- Medical Convention Division, Sunplanet Co., Ltd.
- E-mail: jas57@sunpla-mcv.com
Disclosure of Conflict of Interest (COI)
The disclosure statement of conflict of interest (COI) must be submitted along with the abstract. It is the author’s responsibility to report any real or perceived conflict of interest. Any potential financial gain that may be derived from the reported work may constitute a potential conflict of interest. Disclosure is required in any case in which an individual or company stands to benefit financially from the research performed. Therefore, the onus is on each author to disclose any financial benefit received from an individual or company.
- Inquiries regarding COI disclosure
- Japan Atherosclerosis Society
- E-mail: jas@j-athero.or.jp
Call for Papers
- Submission Type: 公募演題 [Call for Papers]
- *Please select ” Call for Papers ” instead of ” Symposia and the other specified sessions “.
[Call for Papers] Presentation Method
- Free paper：Oral (English presentation)
- Free paper：Poster (English presentation)
- Free paper：Either Oral or Poster (English presentation)
- *Please select one of the above presentation methods.
[Call for Papers] English Category
| 01 | Basic research | Vascular biology, Angiogenesis |
|---|---|---|
| 02 | Vascular pathology | |
| 03 | Inflammation, Cytokine | |
| 04 | Intracellular signaling, Cell | |
| 05 | Hemostasis and thrombosis, Coagulation and fibrinolysis | |
| 06 | Others | |
| 07 |
Atherosclerosis and related diseases |
Hypertension |
| 08 | Diabetes, Endocrine disorders, Metabolic syndrome, Obesity | |
| 09 | Renal disease, CKD | |
| 10 | MASLD/MASH, Fatty liver, Steatohepatitis | |
| 11 | Others | |
| 12 |
Dyslipidemia and its analysis |
Sterol metabolism |
| 13 | Fatty Acid, Triglyceride, Phospholipid | |
| 14 | Lipoprotein metabolism | |
| 15 | Reverse cholesterol transport system, HDL Function | |
| 16 | Lipid absorption and postprandial lipemia | |
| 17 | Familial hypercholesterolemia | |
| 18 | Dyslipidemia, atherosclerosis in women and children | |
| 19 | Dyslipidemia and laboratory medicine | |
| 20 | Others | |
| 21 |
Therapeutic intervention |
Diet therapy/Nutritional therapy/Functional food |
| 22 | Exercise therapy | |
| 23 | Drug therapy, new therapeutics | |
| 24 | Others | |
| 25 |
Evaluation, treatment, and prevention of atherosclerosis |
Epidemiological study, Observational studies |
| 26 | Imaging, Vascular function evaluation | |
| 27 | Acute coronary syndrome, Angina | |
| 28 | Cerebrovascular disease | |
| 29 | Peripheral artery disease | |
| 30 | Aging, Senescence | |
| 31 | Medical checkup, Preventive medicine, Industrial and labor hygiene | |
| 32 | Others | |
| 33 | Medical staff session | Industrial hygiene, Health care, Preventive medicine |
| 34 | Drugs | |
| 35 | Nutritional management | |
| 36 | Laboratory medicine | |
| 37 | Nursing, Care, Primary care | |
| 38 | Others | |
You may be asked to deliver your presentation in a category that is different from the one you specified when submitting your abstract, depending on the program setup. Thank you for your understanding.
Excellent Presentation Award for Young Scientists
The presenter must have been a member for at least two years and be a member of the Japan Atherosclerosis Society under the age of 43 (Age 43 not included) as of January 1 of the year in which the general presentation will be presented at the academic meeting.
*Please select whether or not to apply when submitting your abstract.
Word Limits
- Author information and abstracts must be submitted in English.
- Abstract title must be up to 160 characters.
- Abstract text must be up to 1,400 characters.
- The maximum of 15 authors (first author & co-authors) can be registered.
- The maximum of 10 affiliations (including the affiliation of the first author) can be registered.
- If possible, please structure your abstract with:
・Background:
・Methods:
・Results:
・Conclusion: - Only one chart or diagram is permitted. If you include a chart or diagram, the abstract text should be limited to 600 characters.
Guidelines for Submission
The following browsers can be used with this abstract submission system.
| Firefox | Google Chrome | Microsoft Edge | Safari | |
|---|---|---|---|---|
| Windows | ○ | ○ | ○ | ー |
| Mac | ○ | ○ | ー | ○ |
Password Set-up, Submission, Confirmation and Modifications of Submitted Abstracts
- When submitting an abstract for the first time, registrants will need to decide on an optional password.
- After the submission of your abstract is complete, a registration number (10000 series) will be issued automatically. The submission process for the abstract is complete when this registration number is issued (a message confirming registration will be sent.). If the registration number does not appear on the screen, the submission has not been received.
- Use the confirmation/modification button to make corrections to submitted abstracts. You can modify and check the abstract as many times as you want by entering the registration number and your password until the submission period deadline. You may also delete your submission. Note that if you click the new “Submit (登録)” button each time you modify the contents, there will be duplicate submissions of the same abstract.
- Registrants must keep a record of the registration number and password issued to them. We will not respond to inquiries about registration numbers or passwords to prevent browsing and misuse by third parties.
Registrants Using WEB mail (Gmail, Yahoo! mail, others)
There have been many cases where emails from the organizer or the Secretariat of this Meeting have been sent to ‘Junk’ folders. If you believe that you have not received a message from us, check the Junk folder first. If you have a ‘Spam Mail Folder’ in your WEB mail account, in addition to your mail software’s Junk mail folder, check that as well.
Notes on Entering Information
- Left justify information entered in the column. Do the same in the abstract text column.
- Columns marked as “required” are mandatory. You will not be able to register unless you enter information into these fields.
- The submitted contents will be posted in programs and abstract collections. In principle, the information will be used as is, without changes to the submitted data. Abstracts will be posted as received, even if there are misspellings. Please check your paper before submission.
Fonts
If you will be using Greek fonts, use the symbols in the table below. If you use half-width symbol typefaces (single-byte characters), it will be automatically converted to another typeface (Ex.: αβγ → abc). Please avoid using these typefaces.
| Characters |
α
|
β
|
γ
|
δ
|
ε
|
ζ
|
|---|---|---|---|---|---|---|
| Enter | α | β | γ | δ | ε | ζ |
| Characters |
η
|
θ
|
ι
|
κ
|
λ
|
μ
|
| Enter | η | θ | ι | κ | λ | μ |
| Characters |
ν
|
ξ
|
ο
|
π
|
ρ
|
σ
|
| Enter | ν | ξ | ο | π | ρ | σ |
| Characters |
τ
|
υ
|
φ
|
χ
|
ψ
|
ω
|
| Enter | τ | υ | φ | χ | ψ | ω |
When using English letters and numbers, be sure to distinguish between O (letter) and 0 (number), l (small letter L) and 1 (number), and X (letter) and × (multiplication symbol).
Be sure to distinguish between katakana-hiragana prolonged sound marks (ー) and dashes (―), minus symbols (－) and hyphens (-).
When entering information in English, do not break up single words with hyphens (-).
Japanese characters and decorative fonts that are not compliant with JIS standards cannot be used.
If you use these characters, you will be cautioned when your submission is being confirmed and will be unable to submit your abstract.
Ex.: Number enclosed within a circle (①, ❶)
Superscripts, subscripts, italics, bold letters, line breaks, and underlined words can be used in the title and text of the abstract. Set these according to usage in the table below. Use half-width characters (single-byte characters) for all symbols (<, >, /). Use full-width characters (double-byte characters) (＜, ＞) as inequality signs in the text.
| Character modifications |
Setup | Setting example | Display example |
|---|---|---|---|
| Superscripts | Enclose the beginning and end of text with <SUP> and </SUP> | Na<SUP>＋</SUP> | Na+ |
| Subscript | Enclose the beginning and end of text with <SUB> and </SUB> | H<SUB>2</SUB>O | H2O |
| Italics | Enclose the beginning and end of text with <I> and </I> | <I>c-fos</I> | c-fos |
| Bold | Enclose the beginning and end of text with <B> and </B> | <B>Bold</B> | Bold |
| Underline | Enclose the beginning and end of text with <U> and </U> | <U>Underline</U> | Underline |
Completion of Submission
After your abstract submission is completed, a registration number (10000 series) will be displayed on the screen and an email indicating that your registration is complete will be immediately sent to the email address of the first author registered. This registration number and the confirmation email indicate that your abstract has been received.
If you do not receive an email indicating that your registration is complete, it is possible that the email address you have registered is incorrect. Check that the email address of the first author has been entered correctly on the confirmation/modification page.
Information on the acceptance or rejection of the abstract and the date and time of the accepted presentation will be sent to this address. Make sure to check that you can receive confirmation messages for registration or modifications.
New submission or modification of abstract
The personal information registered will not be used for any purpose other than for the preparation of the 57th Annual Scientific Meeting of the Japan Atherosclerosis Society. We will take the necessary security measures to strictly protect the personal information registered.
Acceptance/Rejection of Abstract
- Submitted abstracts will be reviewed by the program committee and a decision will be made to accept or reject the submission.
- Notification of acceptance/rejection will be sent to the first author’s email address registered during the month of May.